99 related articles for article (PubMed ID: 17467045)
21. Multiomic characterization of high-grade serous ovarian carcinoma: editorial commentary on recent application and consideration for future directions.
Jones TN; Shih IM; Wang TL
Transl Cancer Res; 2023 May; 12(5):1368-1371. PubMed ID: 37304548
[No Abstract] [Full Text] [Related]
22. CORRIGENDUM: GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.
El-Arabey AA; Denizli M; Kanlikilicer P; Bayraktar R; Ivan C; Rashed M; Kabil N; Ozpolat B; Calin GA; Salama SA; Abd-Allah AR; Sood AK; Lopez-Berestein G
Cell Signal; 2022 Jan; 89():110147. PubMed ID: 34772589
[No Abstract] [Full Text] [Related]
23. Correction to: Claudin-10 is a new candidate prognostic marker in metastatic high-grade serous carcinoma.
Davidson B; Doutel D; Holth A; Nymoen DA
Virchows Arch; 2024 May; 484(5):875. PubMed ID: 37261507
[No Abstract] [Full Text] [Related]
24. Clinical significance of microinvasion in borderline ovarian tumors and its impact on surgical management.
Ferrero A; Strada I; Di Marcoberardino B; Maccarini LR; Pozzati F; Rossi M; Biglia N; De Iaco P
Int J Gynecol Cancer; 2012 Sep; 22(7):1158-62. PubMed ID: 22801031
[TBL] [Abstract][Full Text] [Related]
25. Management of Borderline ovarian tumors (BOT): results of a retrospective, single center study in Switzerland.
Kipp B; Vidal A; Lenick D; Christmann-Schmid C
J Ovarian Res; 2023 Jan; 16(1):20. PubMed ID: 36691070
[TBL] [Abstract][Full Text] [Related]
26. A Rare Case of Ovarian Serous Borderline Tumor with Brain Metastasis.
Veran-Taguibao S; Taguibao RAA; Gallegos N; Farzaneh T; Kim R; Lin F; Lu D
Case Rep Pathol; 2019; 2019():2954373. PubMed ID: 31240144
[No Abstract] [Full Text] [Related]
27. Histopathological Patterns of Microinvasion in Ovarian Serous Borderline Tumors.
Cîrstea AE; Stepan AE; Zăvoi RE; Simionescu CE
Curr Health Sci J; 2018; 44(1):19-22. PubMed ID: 30622750
[TBL] [Abstract][Full Text] [Related]
28. Advanced stage micropapillary serous borderline ovarian tumor in a postmenopausal woman: a case report.
Güngör T; Kaba M; Başer E; Yalçın H; Bayramoğlu H; Beşli M
J Turk Ger Gynecol Assoc; 2012; 13(3):208-11. PubMed ID: 24592040
[TBL] [Abstract][Full Text] [Related]
29. Cyberknife radiotherapy and anastrozole for the treatment of advanced progressive low-grade papillary serous ovarian carcinoma: A case report.
Raidoo S; Singh S; Redline R; Debernardo R
Gynecol Oncol Case Rep; 2013; 6():42-4. PubMed ID: 24371718
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors.
Ozer H; Yenicesu G; Arici S; Cetin M; Tuncer E; Cetin A
Diagn Pathol; 2012 Sep; 7():124. PubMed ID: 22995373
[TBL] [Abstract][Full Text] [Related]
31. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
32. Pathologic findings in eight cases of ovarian serous borderline tumors, three with foci of serous carcinoma, that preceded death or morbidity from invasive carcinoma.
Lee KR; Castrillon DH; Nucci MR
Int J Gynecol Pathol; 2001 Oct; 20(4):329-34. PubMed ID: 11603215
[TBL] [Abstract][Full Text] [Related]
33. Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma.
Hogg R; Scurry J; Kim SN; Friedlander M; Hacker N
Gynecol Oncol; 2007 Jul; 106(1):44-51. PubMed ID: 17467045
[TBL] [Abstract][Full Text] [Related]
34. Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion.
Prat J; De Nictolis M
Am J Surg Pathol; 2002 Sep; 26(9):1111-28. PubMed ID: 12218568
[TBL] [Abstract][Full Text] [Related]
35. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
McKenney JK; Balzer BL; Longacre TA
Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
[TBL] [Abstract][Full Text] [Related]
36. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
